Clovis Oncology Inc (NASDAQ: CLVS) Announces Initial Scientific Know-how of FAP-2286 in Autonomous Termed Patient Use Printed in The Journal of Nuclear Medicine

Clovis Oncology Inc (NASDAQ: CLVS) has announced that Professor Dr. Richard P. Baum and Dr. Harshad R. Kulkarni, in combination with 3B Pharmaceuticals, printed a retroactive report. The report talks of their autonomous involvement with FAP-2286 in named-patient usage in The Journal of Nuclear Medicine. Patients were treated with the […]


Clovis Oncology Inc (NASDAQ: CLVS) Announces LuMIERE Scientific Pilot Assessing Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Currently Open for Registration

Clovis Oncology Inc (NASDAQ: CLVS) announced today that the leading scientific site for the Phase 1/2 LuMIERE study of FAP-2286 is now available at the O’NealO’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham (UAB). The O’Neal Comprehensive Cancer Center at UAB is amongst the country’s foremost cancer […]


Analysts Reflect On Various Pharmaceutical Companies Following The End of ASCO

With the American Society of Clinical Oncology Annual Meeting coming to an end, there was a range of abstract presentation highlights for biotech and pharma investors and analysts.¬† Tazeen Ahmad gives Buy rating to Fatem Incyte and ADC therapeutics¬† For instance, BoA Securities analyst Tazeen Ahmad highlighted several companies, including […]